Residual DNA Testing Market - Global Forecast to 2030
商品番号 : SMB-81012
| 出版社 | MarketsandMarkets |
| 出版年月 | 2025年7月 |
| ページ数 | 357 |
| 図表数 | 515 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
この調査レポートでは、残留DNA検査市場を、提供内容（製品およびサービス）、技術（PCR、閾値アッセイ、DNAプローブハイブリダイゼーション、およびその他の技術）、検査タイプ（最終製品リリース検査、バルクロットリリース検査、最終製品リリース検査）、用途（モノクローナル抗体、細胞および遺伝子治療、ワクチン、およびその他の用途）、製品のエンドユーザー（製薬およびバイオテクノロジー企業、CROおよびCDMO、および学術および研究機関）、サービスのエンドユーザー（製薬およびバイオテクノロジー企業および学術および研究機関）、および地域（北米、ヨーロッパ、アジア太平洋、ラテンアメリカ、中東、およびアフリカ）別に分類しています。
本レポートは、残留DNA検査市場を形成する重要な要素、すなわち主要な推進要因、制約要因、課題、そして新たな機会について、詳細な分析を提供しています。また、主要プレーヤーのビジネスモデル、製品・サービス、戦略的取り組み、新規参入、買収、そして残留DNA検査分野に関連する最近の進展について、包括的な分析を提供しています。さらに、本レポートには、残留DNA検査エコシステムにおける新興スタートアップ企業の競争環境評価も含まれています。
The residual DNA testing market is projected to reach USD 0.37 billion by 2030 from USD 0.28 billion in 2025, at a CAGR of 6.0% during the forecast period. The expansion of this market is fueled by multiple factors, including the increasing frequency of approvals for biologics and biosimilars, as well as the implementation of rigorous regulatory frameworks governing the manufacture of biopharmaceutical products. Additionally, advancements in technologies related to residual DNA testing are anticipated to further bolster market growth throughout the forecast period.
残留DNA検査市場は、2025年の2億8,000万米ドルから2030年には3億7,000万米ドルに達し、予測期間中は年平均成長率（CAGR）6.0%で成長すると予測されています。この市場の拡大は、バイオ医薬品およびバイオシミラーの承認頻度の増加、バイオ医薬品の製造を規制する厳格な規制枠組みの導入など、複数の要因によって促進されています。さらに、残留DNA検査関連技術の進歩も、予測期間を通じて市場の成長をさらに後押しすると予想されます。
By technology, the PCR segment accounted for the largest share of the residual DNA testing market in 2024.
By technology, the market is segmented into PCR, threshold Assays, DNA probe hybridization, and other technologies. In 2024, the Polymerase Chain Reaction (PCR) segment commanded the largest share of the market, reflecting its pivotal role in molecular diagnostics. This substantial market share can be primarily attributed to the high sensitivity and specificity offered by PCR, which enables the precise detection of even minute quantities of residual DNA. As a result, PCR effectively minimizes the risk of false positives, a critical factor in ensuring accurate test outcomes. Moreover, the versatility of the PCR technology plays a significant role in its widespread adoption. It can be easily adapted for various test types, making it applicable across a broad spectrum of biopharmaceutical applications. This adaptability, combined with its scalability, allows PCR to be employed in everything from small-scale research studies to large-scale clinical testing, catering to the evolving needs of the biopharmaceutical industry. With its exceptional performance characteristics and flexible applications, the PCR segment continues to be a cornerstone of advancements in molecular biology and diagnostics.
In 2024, by end user, the pharmaceutical & biotechnology companies segment accounted for the largest share of the residual DNA testing services market.
The residual DNA testing services market is categorized into two primary segments: pharmaceutical & biotechnology companies and academic & research institutes. As of 2024, the pharmaceutical & biotechnology companies segment holds the largest share of the market. This substantial growth can be attributed to the increasing emphasis on the development of biologics, which are innovative therapies aimed at treating a variety of diseases, including cancers, autoimmune disorders, and genetic conditions. As the industry evolves, pharmaceutical and biotechnology firms are required to adhere to stringent regulatory standards, which mandate the provision of comprehensive data concerning the entire manufacturing process. This includes the rigorous testing and validation of biological products to ensure their safety and efficacy. Consequently, the necessity for thorough quality inspections and regulatory approvals becomes paramount, driving the demand for residual DNA testing services. These services play a critical role in identifying and quantifying residual DNA left in biologics, ensuring that products meet safety guidelines and are free from contaminants that could pose risks to patients. Moreover, as companies invest in advanced biotechnological research and development, the demand for reliable and accurate testing methods continues to rise. This trend further augments the market for residual DNA testing services, highlighting its essential role in the pharmaceutical landscape. As the sector strives for innovation and compliance, the importance of these testing services will likely increase, underscoring their value in advancing medical science and patient safety.
In 2024, North America accounted for the largest share of the residual DNA testing market.
In 2024, North America emerged as the dominant force in the market, largely due to the strong presence of key industry leaders and a notable expansion in research initiatives aimed at innovating and developing biologics. This growth can be attributed to a significant increase in research and development investments within the life sciences sector, which, in turn, has escalated the demand for residual DNA testing products and services. Additionally, the region benefits from a concentration of numerous global entities, including pharmaceutical companies, biotech firms, and academic institutions, which collectively enhance its leadership position in the market. This collaborative environment fosters innovation and accelerates advancements in biologics, further solidifying North America’s role as a pivotal hub for life sciences R&D.
The primary interviews conducted for this report can be categorized as follows:
- By Respondent: Tier 1-25%, Tier 2-35%, and Tier 3- 40%
- By Designation: CXOs and Directors- 30%, Managers- 45%, and Executives- 25%
- By Region: North America -35%, Europe – 25%, Asia Pacific -15%, Latin America -10%, Middle East- 10%, and Africa- 5%
List of companies profiled in the report:
- Thermo Fisher Scientific Inc. (US)
- Merck KGaA (Germany)
- Eurofins Scientific (Luxembourg)
- Charles River Laboratories (US)
- Bio-Rad Laboratories (US)
- QIAGEN (Germany)
- F. Hoffmann-La Roche Ltd (Switerland)
- Maravai LifeSciences (US)
- FUJIFILM Corporation (Japan)
- SGS Société Générale de Surveillance SA (Switzerland)
- Jiangsu Hillgene Biopharma Co.,Ltd (China)
- Revvity (US)
- Intertek Group plc (UK)
- WuXi AppTec (China)
- Sartorius AG (Germany)
- Lonza (Switzerland)
Research Coverage:
This research report categorizes residual DNA testing market by offering (products and services), technology (PCR, threshold assay, DNA probe hybridization, and other technologies), test type (final product release testing, bulk lot release testing, and final product release testing), application (monoclonal antibodies, cell & gene therapy, vaccines, and other applications), end user for products (pharmaceutical & biotechnology companies, CROs & CDMOs, and academic & research institutes), end user for services (pharmaceutical & biotechnology companies and academic & research institutes), and region (North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa).
The report offers an in-depth examination of the critical elements shaping the residual DNA testing market, including key drivers, constraints, challenges, and emerging opportunities. It presents a comprehensive analysis of leading industry players, detailing their business models, product and service offerings, strategic initiatives, new launches, acquisitions, and recent advancements pertinent to the residual DNA testing sector. Additionally, this report includes a competitive landscape assessment of emerging startups within the residual DNA testing ecosystem.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the residual DNA testing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on the key market drivers, restraints, challenges, trends, and opportunities.
The report provides insights on the following:
- Analysis of key drivers (Increase in biologics and biosimilars approvals, stringent regulatory compliance requirements, technological advancements in DNA quantification and detection, increasing cell culture contamination risks, rising investments in R&D spending), restraints (high cost of advanced testing techniques, lack of standardization across testing protocols), opportunities (application in novel modalities such as mRNA vaccines, cell therapies, and gene therapies, growth opportunities in emerging markets, integration with continuous and accelerated bioprocessing, rising outsourcing to CROs and CDMOs), and challenges (complexity in sample preparation and assay validation) are influencing the growth of the residual DNA testing market.
- Product Development/Innovation: Detailed insights on newly launched products of the residual DNA testing market.
- Market Development: Comprehensive information about lucrative markets – the report analyses the residual DNA testing market across varied regions.
- Market Diversification: Exhaustive information about new products and services, recent developments, and investments in the residual DNA testing market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players, including Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), and Eurofins Scientific (Luxembourg), among others, offering products and services for the residual DNA testing market. Other companies in this market include TransGen Biotech Co., Ltd. (China), Vazyme International LLC (China), and EagleBio (US).
Table of Contents
1 INTRODUCTION 36
1.1 STUDY OBJECTIVES 36
1.2 MARKET DEFINITION 36
1.3 STUDY SCOPE 37
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 37
1.3.2 INCLUSIONS & EXCLUSIONS 38
1.3.3 YEARS CONSIDERED 39
1.3.4 CURRENCY CONSIDERED 39
1.4 STAKEHOLDERS 39
2 RESEARCH METHODOLOGY 40
2.1 RESEARCH DATA 40
2.1.1 SECONDARY DATA 41
2.1.1.1 Key sources of secondary data 41
2.1.1.2 Key objectives of secondary research 41
2.1.2 PRIMARY DATA 42
2.1.2.1 Breakdown of primaries 42
2.1.2.2 Key objectives of primary research 42
2.2 MARKET ESTIMATION METHODOLOGY 43
2.2.1 MARKET ESTIMATION 43
2.2.1.1 Company revenue analysis (bottom-up approach) 43
2.2.1.2 Insights of primary experts 45
2.2.2 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH) 46
2.3 MARKET GROWTH RATE PROJECTIONS 47
2.4 DATA TRIANGULATION 49
2.5 STUDY ASSUMPTIONS 50
2.6 RESEARCH LIMITATIONS 51
2.7 RISK ANALYSIS 51
3 EXECUTIVE SUMMARY 52
4 PREMIUM INSIGHTS 57
4.1 RESIDUAL DNA TESTING MARKET OVERVIEW 57
4.2 NORTH AMERICA: RESIDUAL DNA TESTING MARKET, BY TEST TYPE AND COUNTRY 58
4.3 RESIDUAL DNA TESTING PRODUCTS MARKET SHARE, BY END USER, 2024 58
4.4 RESIDUAL DNA TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 59
5 MARKET OVERVIEW 60
5.1 INTRODUCTION 60
5.2 MARKET DYNAMICS 60
5.2.1 DRIVERS 61
5.2.1.1 Increasing number of biologics and biosimilar approvals 61
5.2.1.2 Stringent regulatory compliance requirements 62
5.2.1.3 Technological advancements in DNA quantification and detection 63
5.2.1.4 Increasing risk of cell culture contamination 63
5.2.1.5 Rising biopharmaceutical R&D investments 64
5.2.2 RESTRAINTS 64
5.2.2.1 High costs of advanced testing techniques 64
5.2.2.2 Lack of standardization across testing protocols 65
5.2.3 OPPORTUNITIES 65
5.2.3.1 Rising number of applications in novel modalities 65
5.2.3.2 High growth opportunities in emerging markets 67
5.2.3.3 Integration with continuous and accelerated bioprocessing 67
5.2.3.4 Rising outsourcing to CROs and CDMOs 68
5.2.4 CHALLENGES 68
5.2.4.1 Complexity in sample preparation and assay validation 68
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 69
5.4 PRICING ANALYSIS 69
5.4.1 AVERAGE SELLING PRICE TREND OF RESIDUAL DNA TESTING PRODUCTS,
BY KEY PLAYER, 2022–2024 70
5.4.2 AVERAGE SELLING PRICE TREND OF RESIDUAL DNA TESTING PRODUCTS,
BY REGION, 2022–2024 71
5.5 VALUE CHAIN ANALYSIS 73
5.6 ECOSYSTEM ANALYSIS 74
5.6.1 ROLE IN ECOSYSTEM 76
5.7 INVESTMENT & FUNDING SCENARIO 77
5.8 TECHNOLOGY ANALYSIS 78
5.8.1 KEY TECHNOLOGIES 78
5.8.1.1 Quantitative PCR (qPCR) 78
5.8.1.2 Droplet digital PCR (ddPCR) 78
5.8.1.3 Next-generation sequencing (NGS) 79
5.8.2 COMPLEMENTARY TECHNOLOGIES 79
5.8.2.1 Automated magnetic bead-based DNA extraction 79
5.8.2.2 Capillary electrophoresis 79
5.8.2.3 Nanopore sequencing 79
5.8.3 ADJACENT TECHNOLOGIES 80
5.8.3.1 High-performance liquid chromatography (HPLC) 80
5.8.3.2 Electron microscopy 80
5.8.3.3 Mass spectrometry 80
5.9 PATENT ANALYSIS 81
5.9.1 LIST OF KEY PATENTS 82
5.10 KEY CONFERENCES & EVENTS, 2025–2026 83
5.11 REGULATORY ANALYSIS 83
5.11.1 REGULATORY FRAMEWORK 83
5.11.1.1 North America 84
5.11.1.1.1 US 84
5.11.1.1.2 Canada 84
5.11.1.2 Europe 84
5.11.1.2.1 UK 85
5.11.1.3 Asia Pacific 85
5.11.1.3.1 China 85
5.11.1.3.2 Japan 85
5.11.1.3.3 India 85
5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 86
5.12 PORTER’S FIVE FORCES ANALYSIS 87
5.12.1 BARGAINING POWER OF SUPPLIERS 89
5.12.2 BARGAINING POWER OF BUYERS 89
5.12.3 THREAT OF NEW ENTRANTS 89
5.12.4 THREAT OF SUBSTITUTES 89
5.12.5 INTENSITY OF COMPETITIVE RIVALRY 90
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 90
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 90
5.13.2 KEY BUYING CRITERIA, BY END USER 91
5.14 IMPACT OF AI/GEN AI ON RESIDUAL DNA TESTING MARKET 92
5.14.1 MARKET POTENTIAL OF AI IN RESIDUAL DNA TESTING 92
5.14.2 AI USE CASES 93
5.14.3 KEY COMPANIES IMPLEMENTING AI/GEN AI 93
5.14.4 FUTURE OF AI/GEN AI IN RESIDUAL DNA TESTING MARKET 93
5.15 TRADE DATA ANALYSIS 94
5.15.1 IMPORT DATA FOR HS CODE 9027, 2020–2024 94
5.15.2 EXPORT DATA FOR HS CODE 9027, 2020–2024 95
5.16 IMPACT OF 2025 US TARIFF ON RESIDUAL DNA TESTING MARKET 95
5.16.1 KEY TARIFF RATES 96
5.16.2 PRICE IMPACT ANALYSIS 97
5.16.3 IMPACT ON COUNTRIES/REGIONS 98
5.16.3.1 North America 98
5.16.3.1.1 US 98
5.16.3.2 Europe 98
5.16.3.3 Asia Pacific 98
5.16.3.4 Rest of the World 98
5.16.4 IMPACT ON END-USE INDUSTRIES 99
5.16.4.1 Pharmaceutical & biotechnology companies 99
5.16.4.2 CROs & CDMOs 99
5.16.4.3 Academic & research institutes 99
6 RESIDUAL DNA TESTING MARKET, BY OFFERING 100
6.1 INTRODUCTION 101
6.2 PRODUCTS 101
6.2.1 CONSUMABLES 105
6.2.1.1 Increasing focus on development of biologics and biosimilars to propel segment growth 105
6.2.2 INSTRUMENTS & SOFTWARE 109
6.2.2.1 Continuous advancement in analytical technologies to fuel segment growth 109
6.3 SERVICES 112
6.3.1 STRINGENT REGULATORY STANDARDS TO PROMOTE MARKET GROWTH 112
7 RESIDUAL DNA TESTING MARKET, BY TEST TYPE 116
7.1 INTRODUCTION 117
7.2 FINAL PRODUCT RELEASE TESTING 117
7.2.1 FAVORABLE REGULATORY MANDATES AND BIOLOGICS INNOVATION TO FUEL MARKET GROWTH 117
7.3 BULK LOT RELEASE TESTING 121
7.3.1 INCREASING BIOLOGIC COMPLEXITY TO FUEL MARKET GROWTH 121
7.4 RAW MATERIAL TESTING 124
7.4.1 ENHANCED FOCUS ON PRODUCT SAFETY AND REGULATORY COMPLIANCE TO AUGMENT MARKET GROWTH 124
8 RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY 128
8.1 INTRODUCTION 129
8.2 POLYMERASE CHAIN REACTION 129
8.2.1 HIGH THROUGHPUT DETECTION TO SUPPORT SEGMENT DOMINANCE 129
8.3 THRESHOLD ASSAYS 133
8.3.1 HIGH SPECIFICITY OF DNA DETECTION AT LOW CONCENTRATION TO FUEL MARKET GROWTH 133
8.4 DNA PROBE HYBRIDIZATION 136
8.4.1 EASY-TO-USE PORTFOLIO TO BOOST ADOPTION OF DNA PROBE HYBRIDIZATION 136
8.5 OTHER TECHNOLOGIES 140
9 RESIDUAL DNA TESTING MARKET, BY APPLICATION 144
9.1 INTRODUCTION 145
9.2 MONOCLONAL ANTIBODIES 145
9.2.1 EXPANSION OF BIOSIMILAR PIPELINE TO AID MARKET GROWTH 145
9.3 CELL & GENE THERAPY 149
9.3.1 RISING POPULARITY OF VIRAL VECTOR-BASED SYSTEMS AND INCREASING REGULATORY APPROVALS TO AID MARKET GROWTH 149
9.4 VACCINES 152
9.4.1 PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET 152
9.5 OTHER APPLICATIONS 156
10 RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER 159
10.1 INTRODUCTION 160
10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 160
10.2.1 HIGH BIOPHARMACEUTICAL R&D SPENDING AND INCREASED REGULATORY PRESSURE TO FUEL MARKET GROWTH 160
10.3 CROS & CDMOS 164
10.3.1 FOCUS ON BIOLOGICS DEVELOPMENT AND CDMO FACILITY EXPANSION TO BOOST MARKET GROWTH 164
10.4 ACADEMIC & RESEARCH INSTITUTES 167
10.4.1 SURGE IN R&D ACTIVITIES FOR DEVELOPMENT OF ADVANCED THERAPIES TO DRIVE MARKET GROWTH 167
11 RESIDUAL DNA TESTING SERVICES MARKET, BY END USER 171
11.1 INTRODUCTION 172
11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 172
11.2.1 SURGE IN R&D INVESTMENTS IN BIOPHARMACEUTICAL INNOVATION TO PROPEL MARKET GROWTH 172
11.3 ACADEMIC & RESEARCH INSTITUTES 176
11.3.1 SSLIMITED IN-HOUSE CAPABILITIES TO DRIVE OUTSOURCING 176
12 RESIDUAL DNA TESTING MARKET, BY REGION 180
12.1 INTRODUCTION 181
12.2 NORTH AMERICA 182
12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 183
12.2.2 US 188
12.2.2.1 US to dominate North American residual DNA testing market during study period 188
12.2.3 CANADA 191
12.2.3.1 Increasing government support for biologics manufacturing and rising research funding to propel market growth 191
12.3 EUROPE 194
12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 194
12.3.2 GERMANY 198
12.3.2.1 Increasing investments in biopharma and rising focus on developing manufacturing capabilities to drive market 198
12.3.3 UK 201
12.3.3.1 Booming life science industry and growing focus on vaccine development to aid market growth 201
12.3.4 FRANCE 204
12.3.4.1 Growing biotechnology sector and rising research funding to drive market 204
12.3.5 ITALY 207
12.3.5.1 High R&D investments in life sciences research to augment market growth 207
12.3.6 SPAIN 210
12.3.6.1 Increasing number of biotech companies to favor market growth 210
12.3.7 REST OF EUROPE 213
12.4 ASIA PACIFIC 215
12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 216
12.4.2 CHINA 221
12.4.2.1 High R&D expenditure and favorable strategic alliances to propel market growth 221
12.4.3 JAPAN 224
12.4.3.1 Favorable government initiatives for drug development to support market growth 224
12.4.4 INDIA 227
12.4.4.1 Increasing R&D investments and funding for life science research to support market growth 227
12.4.5 SOUTH KOREA 230
12.4.5.1 Increasing strategic alliances and investments to spur market growth 230
12.4.6 AUSTRALIA 233
12.4.6.1 Booming life science sector to fuel market growth 233
12.4.7 REST OF ASIA PACIFIC 236
12.5 LATIN AMERICA 238
12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 239
12.5.2 BRAZIL 242
12.5.2.1 Substantial R&D investments by pharmaceutical companies to fuel market growth 242
12.5.3 MEXICO 245
12.5.3.1 Rising government support for biopharmaceutical production to drive market 245
12.5.4 REST OF LATIN AMERICA 248
12.6 MIDDLE EAST 250
12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST 251
12.6.2 GCC COUNTRIES 254
12.6.2.1 Kingdom of Saudi Arabia 258
12.6.2.1.1 Increasing R&D investments in pharmaceutical industries to drive market 258
12.6.2.2 UAE 261
12.6.2.2.1 Investments in biopharma sector to offer growth opportunities 261
12.6.2.3 Rest of GCC Countries 263
12.6.3 REST OF MIDDLE EAST 266
12.7 AFRICA 269
12.7.1 RISING PREVALENCE OF CHRONIC DISEASES AND INCREASING FUNDING FOR BIOPHARMA SECTOR TO FUEL MARKET GROWTH 269
12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 269
13 COMPETITIVE LANDSCAPE 273
13.1 INTRODUCTION 273
13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 273
13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN RESIDUAL DNA TESTING MARKET 274
13.3 REVENUE ANALYSIS, 2020–2024 275
13.4 MARKET SHARE ANALYSIS, 2024 275
13.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 278
13.5.1 STARS 278
13.5.2 EMERGING LEADERS 278
13.5.3 PERVASIVE PLAYERS 278
13.5.4 PARTICIPANTS 278
13.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 280
13.5.5.1 Company footprint 280
13.5.5.2 Region footprint 281
13.5.5.3 Offering footprint 282
13.5.5.4 Technology footprint 283
13.5.5.5 Test type footprint 284
13.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 285
13.6.1 PROGRESSIVE COMPANIES 285
13.6.2 RESPONSIVE COMPANIES 285
13.6.3 DYNAMIC COMPANIES 285
13.6.4 STARTING BLOCKS 285
13.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 287
13.6.5.1 Detailed list of key startups/SMEs 287
13.6.5.2 Competitive benchmarking of Key startups/SMEs 288
13.7 COMPANY VALUATION & FINANCIAL METRICS 289
13.7.1 FINANCIAL METRICS 289
13.7.2 COMPANY VALUATION 289
13.8 BRAND/PRODUCT COMPARISON 290
13.9 COMPETITIVE SCENARIO 291
13.9.1 PRODUCT LAUNCHES 291
13.9.2 DEALS 292
13.9.3 OTHER DEVELOPMENTS 292
14 COMPANY PROFILES 293
14.1 KEY PLAYERS 293
14.1.1 THERMO FISHER SCIENTIFIC INC. 293
14.1.1.1 Business overview 293
14.1.1.2 Products/Services offered 295
14.1.1.3 Recent developments 296
14.1.1.3.1 Expansions 296
14.1.1.3.2 Other developments 296
14.1.1.4 MnM view 297
14.1.1.4.1 Key strengths 297
14.1.1.4.2 Strategic choices 297
14.1.1.4.3 Weaknesses & competitive threats 297
14.1.2 CHARLES RIVER LABORATORIES 298
14.1.2.1 Business overview 298
14.1.2.2 Products/Services offered 299
14.1.2.3 Recent developments 300
14.1.2.3.1 Expansions 300
14.1.2.4 MnM view 300
14.1.2.4.1 Key strengths 300
14.1.2.4.2 Strategic choices 300
14.1.2.4.3 Weaknesses & competitive threats 300
14.1.3 F. HOFFMANN-LA ROCHE LTD. 301
14.1.3.1 Business overview 301
14.1.3.2 Products/Services offered 302
14.1.3.3 Recent developments 303
14.1.3.3.1 Product launches 303
14.1.3.4 MnM view 303
14.1.3.4.1 Key strengths 303
14.1.3.4.2 Strategic choices 303
14.1.3.4.3 Weaknesses & competitive threats 303
14.1.4 MERCK KGAA 304
14.1.4.1 Business overview 304
14.1.4.2 Products/Services offered 305
14.1.4.3 Recent developments 306
14.1.4.3.1 Product launches 306
14.1.4.3.2 Expansions 306
14.1.4.4 MnM view 307
14.1.4.4.1 Key strengths 307
14.1.4.4.2 Strategic choices 307
14.1.4.4.3 Weaknesses & competitive threats 307
14.1.5 MARAVAI LIFESCIENCES 308
14.1.5.1 Business overview 308
14.1.5.2 Products/Services offered 310
14.1.5.3 Recent developments 311
14.1.5.3.1 Deals 311
14.1.5.4 MnM view 311
14.1.5.4.1 Key strengths 311
14.1.5.4.2 Strategic choices 311
14.1.5.4.3 Weaknesses & competitive threats 311
14.1.6 EUROFINS SCIENTIFIC 312
14.1.6.1 Business overview 312
14.1.6.2 Products/Services offered 314
14.1.6.3 Recent developments 314
14.1.6.3.1 Deals 314
14.1.7 BIO-RAD LABORATORIES, INC. 315
14.1.7.1 Business overview 315
14.1.7.2 Products/Services offered 317
14.1.7.3 Recent developments 318
14.1.7.3.1 Deals 318
14.1.8 QIAGEN 319
14.1.8.1 Business overview 319
14.1.8.2 Products/Services offered 321
14.1.8.3 Recent developments 321
14.1.8.3.1 Product launches 321
14.1.9 FUJIFILM CORPORATION 322
14.1.9.1 Business overview 322
14.1.9.2 Products/Services offered 324
14.1.10 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA. 325
14.1.10.1 Business overview 325
14.1.10.2 Products/Services offered 326
14.1.11 HILLGENE BIOPHARMA CO., LTD. 327
14.1.11.1 Business overview 327
14.1.11.2 Products/Services offered 329
14.1.12 REVVITY 330
14.1.12.1 Business overview 330
14.1.12.2 Products/Services offered 332
14.1.12.3 Recent developments 332
14.1.12.3.1 Product launches 332
14.1.13 INTERTEK GROUP PLC 333
14.1.13.1 Business overview 333
14.1.13.2 Products/Services offered 334
14.1.14 SARTORIUS AG 335
14.1.14.1 Business overview 335
14.1.14.2 Products/Services offered 336
14.1.15 LONZA 337
14.1.15.1 Business overview 337
14.1.15.2 Products/Services offered 338
14.1.16 WUXI APPTEC 339
14.1.16.1 Business overview 339
14.1.16.2 Products/Services offered 340
14.2 OTHER PLAYERS 341
14.2.1 TRANSGEN BIOTECH CO., LTD. 341
14.2.2 EAGLEBIO 342
14.2.3 YEASEN 343
14.2.4 ACROBIOSYSTEMS 344
14.2.5 CREATIVE BIOGENE 345
14.2.6 MINERVA BIOLABS GMBH 346
14.2.7 CREATIVE PROTEOMICS 347
14.2.8 AVANCE BIOSCIENCES 348
14.2.9 GENERI BIOTECH 349
15 APPENDIX 350
15.1 DISCUSSION GUIDE 350
15.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 353
15.3 CUSTOMIZATION OPTIONS 355
15.4 RELATED REPORTS 355
15.5 AUTHOR DETAILS 356
LIST OF TABLES
TABLE 1 RESIDUAL DNA TESTING MARKET: INCLUSIONS & EXCLUSIONS 38
TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS 48
TABLE 3 RESIDUAL DNA TESTING MARKET: RISK ANALYSIS 51
TABLE 4 RESIDUAL DNA TESTING MARKET: IMPACT ANALYSIS OF DRIVERS,
RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 61
TABLE 5 LIST OF FDA-APPROVED BIOSIMILAR PRODUCTS, 2022–2024 62
TABLE 6 KEY PRODUCT APPROVALS IN GENE THERAPY MARKET, 2022–2024 66
TABLE 7 AVERAGE SELLING PRICE TREND OF RESIDUAL DNA TESTING PRODUCTS,
BY KEY PLAYER, 2022–2024 (USD MILLION) 70
TABLE 8 AVERAGE SELLING PRICE TREND OF RESIDUAL DNA QUANTIFICATION KITS,
BY REGION, 2022–2024 (USD MILLION) 71
TABLE 9 AVERAGE SELLING PRICE TREND OF PCR INSTRUMENTS,
BY REGION, 2022–2024 (USD MILLION) 72
TABLE 10 RESIDUAL DNA TESTING MARKET: ROLE IN ECOSYSTEM 76
TABLE 11 MAJOR INVESTMENT AND FUNDING ACTIVITIES IN RESIDUAL DNA TESTING MARKET, BY KEY PLAYER, 2022−2025 77
TABLE 12 RESIDUAL DNA TESTING MARKET: INNOVATIONS AND PATENT
REGISTRATIONS, 2024 82
TABLE 13 RESIDUAL DNA TESTING MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025–DECEMBER 2026 83
TABLE 14 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 86
TABLE 15 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 86
TABLE 16 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 87
TABLE 17 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 87
TABLE 18 RESIDUAL DNA TESTING MARKET: PORTER’S FIVE FORCES 88
TABLE 19 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY OFFERING (%) 90
TABLE 20 KEY BUYING CRITERIA, BY END USER 91
TABLE 21 LIST OF KEY COMPANIES IMPLEMENTING AI/GEN AI IN RESIDUAL
DNA TESTING MARKET 93
TABLE 22 RESIDUAL DNA TESTING MARKET: IMPORT DATA FOR HS CODE 9027,
2020–2024 (USD THOUSAND) 94
TABLE 23 RESIDUAL DNA TESTING MARKET: EXPORT DATA FOR HS CODE 9027,
2020–2024 (USD THOUSAND) 95
TABLE 24 US ADJUSTED RECIPROCAL TARIFF RATES 96
TABLE 25 PRODUCT/COMPONENT-RELATED TARIFFS FOR
RESIDUAL DNA TESTING PRODUCTS 97
TABLE 26 CRITICAL COMPONENTS EXPOSED TO TARIFF CHANGES 97
TABLE 27 RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 101
TABLE 28 RESIDUAL DNA TESTING PRODUCTS MARKET, BY REGION,
2023–2030 (USD MILLION) 102
TABLE 29 NORTH AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 102
TABLE 30 EUROPE: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 103
TABLE 31 ASIA PACIFIC: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 103
TABLE 32 LATIN AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 104
TABLE 33 MIDDLE EAST: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY REGION, 2023–2030 (USD MILLION) 104
TABLE 34 GCC COUNTRIES: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 104
TABLE 35 RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 105
TABLE 36 RESIDUAL DNA TESTING CONSUMABLES MARKET, BY REGION,
2023–2030 (USD MILLION) 106
TABLE 37 NORTH AMERICA: RESIDUAL DNA TESTING CONSUMABLES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 106
TABLE 38 EUROPE: RESIDUAL DNA TESTING CONSUMABLES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 107
TABLE 39 ASIA PACIFIC: RESIDUAL DNA TESTING CONSUMABLES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 107
TABLE 40 LATIN AMERICA: RESIDUAL DNA TESTING CONSUMABLES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 108
TABLE 41 MIDDLE EAST: RESIDUAL DNA TESTING CONSUMABLES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 108
TABLE 42 GCC COUNTRIES: RESIDUAL DNA TESTING CONSUMABLES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 108
TABLE 43 RESIDUAL DNA TESTING INSTRUMENTS & SOFTWARE MARKET,
BY REGION, 2023–2030 (USD MILLION) 109
TABLE 44 NORTH AMERICA: RESIDUAL DNA TESTING INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 110
TABLE 45 EUROPE: RESIDUAL DNA TESTING INSTRUMENTS & SOFTWARE MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 110
TABLE 46 ASIA PACIFIC: RESIDUAL DNA TESTING INSTRUMENTS & SOFTWARE MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 111
TABLE 47 LATIN AMERICA: RESIDUAL DNA TESTING INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 111
TABLE 48 MIDDLE EAST: RESIDUAL DNA TESTING INSTRUMENTS & SOFTWARE MARKET,
BY REGION, 2023–2030 (USD MILLION) 111
TABLE 49 GCC COUNTRIES: RESIDUAL DNA TESTING INSTRUMENTS & SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 112
TABLE 50 RESIDUAL DNA TESTING SERVICES MARKET, BY REGION,
2023–2030 (USD MILLION) 113
TABLE 51 NORTH AMERICA: RESIDUAL DNA TESTING SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 113
TABLE 52 EUROPE: RESIDUAL DNA TESTING SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 114
TABLE 53 ASIA PACIFIC: RESIDUAL DNA TESTING SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 114
TABLE 54 LATIN AMERICA: RESIDUAL DNA TESTING SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 115
TABLE 55 MIDDLE EAST: RESIDUAL DNA TESTING SERVICES MARKET,
BY REGION, 2023–2030 (USD MILLION) 115
TABLE 56 GCC COUNTRIES: RESIDUAL DNA TESTING SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 115
TABLE 57 RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 117
TABLE 58 RESIDUAL DNA FINAL PRODUCT RELEASE TESTING MARKET,
BY REGION, 2023–2030 (USD MILLION) 118
TABLE 59 NORTH AMERICA: RESIDUAL DNA FINAL PRODUCT RELEASE TESTING MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 118
TABLE 60 EUROPE: RESIDUAL DNA FINAL PRODUCT RELEASE TESTING MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 119
TABLE 61 ASIA PACIFIC: RESIDUAL DNA FINAL PRODUCT RELEASE TESTING MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 119
TABLE 62 LATIN AMERICA: RESIDUAL DNA FINAL PRODUCT RELEASE TESTING MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 120
TABLE 63 MIDDLE EAST: RESIDUAL DNA FINAL PRODUCT RELEASE TESTING MARKET,
BY REGION, 2023–2030 (USD MILLION) 120
TABLE 64 GCC COUNTRIES: RESIDUAL DNA FINAL PRODUCT RELEASE TESTING MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 120
TABLE 65 RESIDUAL DNA BULK LOT RELEASE TESTING MARKET,
BY REGION, 2023–2030 (USD MILLION) 121
TABLE 66 NORTH AMERICA: RESIDUAL DNA BULK LOT RELEASE TESTING MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 122
TABLE 67 EUROPE: RESIDUAL DNA BULK LOT RELEASE TESTING MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 122
TABLE 68 ASIA PACIFIC: RESIDUAL DNA BULK LOT RELEASE TESTING MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 123
TABLE 69 LATIN AMERICA: RESIDUAL DNA BULK LOT RELEASE TESTING MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 123
TABLE 70 MIDDLE EAST: RESIDUAL DNA BULK LOT RELEASE TESTING MARKET,
BY REGION, 2023–2030 (USD MILLION) 123
TABLE 71 GCC COUNTRIES: RESIDUAL DNA BULK LOT RELEASE TESTING MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 124
TABLE 72 RESIDUAL DNA RAW MATERIAL TESTING MARKET, BY REGION,
2023–2030 (USD MILLION) 125
TABLE 73 NORTH AMERICA: RESIDUAL DNA RAW MATERIAL TESTING MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 125
TABLE 74 EUROPE: RESIDUAL DNA RAW MATERIAL TESTING MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 126
TABLE 75 ASIA PACIFIC: RESIDUAL DNA RAW MATERIAL TESTING MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 126
TABLE 76 LATIN AMERICA: RESIDUAL DNA RAW MATERIAL TESTING MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 127
TABLE 77 MIDDLE EAST: RESIDUAL DNA RAW MATERIAL TESTING MARKET,
BY REGION, 2023–2030 (USD MILLION) 127
TABLE 78 GCC COUNTRIES: RESIDUAL DNA RAW MATERIAL TESTING MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 127
TABLE 79 RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY, 2023–2030 (USD MILLION) 129
TABLE 80 RESIDUAL DNA TESTING MARKET FOR POLYMERASE CHAIN REACTION,
BY REGION, 2023–2030 (USD MILLION) 130
TABLE 81 NORTH AMERICA: RESIDUAL DNA TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION) 130
TABLE 82 EUROPE: RESIDUAL DNA TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION) 131
TABLE 83 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION) 131
TABLE 84 LATIN AMERICA: RESIDUAL DNA TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION) 132
TABLE 85 MIDDLE EAST: RESIDUAL DNA TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2023–2030 (USD MILLION) 132
TABLE 86 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2023–2030 (USD MILLION) 132
TABLE 87 RESIDUAL DNA TESTING MARKET FOR THRESHOLD ASSAYS,
BY REGION, 2023–2030 (USD MILLION) 133
TABLE 88 NORTH AMERICA: RESIDUAL DNA TESTING MARKET FOR THRESHOLD ASSAYS,
BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 89 EUROPE: RESIDUAL DNA TESTING MARKET FOR THRESHOLD ASSAYS,
BY COUNTRY, 2023–2030 (USD MILLION) 134
TABLE 90 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET FOR THRESHOLD ASSAYS,
BY COUNTRY, 2023–2030 (USD MILLION) 135
TABLE 91 LATIN AMERICA: RESIDUAL DNA TESTING MARKET FOR THRESHOLD ASSAYS,
BY COUNTRY, 2023–2030 (USD MILLION) 135
TABLE 92 MIDDLE EAST: RESIDUAL DNA TESTING MARKET FOR THRESHOLD ASSAYS,
BY REGION, 2023–2030 (USD MILLION) 135
TABLE 93 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET FOR THRESHOLD ASSAYS,
BY COUNTRY, 2023–2030 (USD MILLION) 136
TABLE 94 RESIDUAL DNA TESTING MARKET FOR DNA PROBE HYBRIDIZATION,
BY REGION, 2023–2030 (USD MILLION) 137
TABLE 95 NORTH AMERICA: RESIDUAL DNA TESTING MARKET FOR DNA PROBE HYBRIDIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 137
TABLE 96 EUROPE: RESIDUAL DNA TESTING MARKET FOR DNA PROBE HYBRIDIZATION,
BY COUNTRY, 2023–2030 (USD MILLION) 138
TABLE 97 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET FOR DNA PROBE HYBRIDIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 138
TABLE 98 LATIN AMERICA: RESIDUAL DNA TESTING MARKET FOR DNA PROBE HYBRIDIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 139
TABLE 99 MIDDLE EAST: RESIDUAL DNA TESTING MARKET FOR DNA PROBE HYBRIDIZATION, BY REGION, 2023–2030 (USD MILLION) 139
TABLE 100 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET FOR DNA PROBE HYBRIDIZATION, BY COUNTRY, 2023–2030 (USD MILLION) 139
TABLE 101 RESIDUAL DNA TESTING MARKET FOR OTHER TECHNOLOGIES,
BY REGION, 2023–2030 (USD MILLION) 140
TABLE 102 NORTH AMERICA: RESIDUAL DNA TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 141
TABLE 103 EUROPE: RESIDUAL DNA TESTING MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2023–2030 (USD MILLION) 141
TABLE 104 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2023–2030 (USD MILLION) 142
TABLE 105 LATIN AMERICA: RESIDUAL DNA TESTING MARKET FOR OTHER TECHNOLOGIES,
BY COUNTRY, 2023–2030 (USD MILLION) 142
TABLE 106 MIDDLE EAST: RESIDUAL DNA TESTING MARKET FOR OTHER TECHNOLOGIES,
BY REGION, 2023–2030 (USD MILLION) 143
TABLE 107 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2023–2030 (USD MILLION) 143
TABLE 108 RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 145
TABLE 109 RESIDUAL DNA TESTING MARKET FOR MONOCLONAL ANTIBODIES,
BY REGION, 2023–2030 (USD MILLION) 146
TABLE 110 NORTH AMERICA: RESIDUAL DNA TESTING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 146
TABLE 111 EUROPE: RESIDUAL DNA TESTING MARKET FOR MONOCLONAL ANTIBODIES,
BY COUNTRY, 2023–2030 (USD MILLION) 147
TABLE 112 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 147
TABLE 113 LATIN AMERICA: RESIDUAL DNA TESTING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 148
TABLE 114 MIDDLE EAST: RESIDUAL DNA TESTING MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2023–2030 (USD MILLION) 148
TABLE 115 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2023–2030 (USD MILLION) 148
TABLE 116 RESIDUAL DNA TESTING MARKET FOR CELL & GENE THERAPY,
BY REGION, 2023–2030 (USD MILLION) 149
TABLE 117 NORTH AMERICA: RESIDUAL DNA TESTING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 118 EUROPE: RESIDUAL DNA TESTING MARKET FOR CELL & GENE THERAPY,
BY COUNTRY, 2023–2030 (USD MILLION) 150
TABLE 119 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET FOR CELL & GENE THERAPY,
BY COUNTRY, 2023–2030 (USD MILLION) 151
TABLE 120 LATIN AMERICA: RESIDUAL DNA TESTING MARKET FOR CELL & GENE THERAPY,
BY COUNTRY, 2023–2030 (USD MILLION) 151
TABLE 121 MIDDLE EAST: RESIDUAL DNA TESTING MARKET FOR CELL & GENE THERAPY,
BY REGION, 2023–2030 (USD MILLION) 151
TABLE 122 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET FOR CELL & GENE THERAPY, BY COUNTRY, 2023–2030 (USD MILLION) 152
TABLE 123 RESIDUAL DNA TESTING MARKET FOR VACCINES, BY REGION,
2023–2030 (USD MILLION) 153
TABLE 124 NORTH AMERICA: RESIDUAL DNA TESTING MARKET FOR VACCINES,
BY COUNTRY, 2023–2030 (USD MILLION) 153
TABLE 125 EUROPE: RESIDUAL DNA TESTING MARKET FOR VACCINES,
BY COUNTRY, 2023–2030 (USD MILLION) 154
TABLE 126 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET FOR VACCINES,
BY COUNTRY, 2023–2030 (USD MILLION) 154
TABLE 127 LATIN AMERICA: RESIDUAL DNA TESTING MARKET FOR VACCINES,
BY COUNTRY, 2023–2030 (USD MILLION) 155
TABLE 128 MIDDLE EAST: RESIDUAL DNA TESTING MARKET FOR VACCINES,
BY REGION, 2023–2030 (USD MILLION) 155
TABLE 129 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET FOR VACCINES,
BY COUNTRY, 2023–2030 (USD MILLION) 155
TABLE 130 RESIDUAL DNA TESTING MARKET FOR OTHER APPLICATIONS,
BY REGION, 2023–2030 (USD MILLION) 156
TABLE 131 NORTH AMERICA: RESIDUAL DNA TESTING MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 156
TABLE 132 EUROPE: RESIDUAL DNA TESTING MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 157
TABLE 133 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 157
TABLE 134 LATIN AMERICA: RESIDUAL DNA TESTING MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 158
TABLE 135 MIDDLE EAST: RESIDUAL DNA TESTING MARKET FOR OTHER APPLICATIONS,
BY REGION, 2023–2030 (USD MILLION) 158
TABLE 136 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2023–2030 (USD MILLION) 158
TABLE 137 RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER,
2023–2030 (USD MILLION) 160
TABLE 138 RESIDUAL DNA TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 161
TABLE 139 NORTH AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2023–2030 (USD MILLION) 161
TABLE 140 EUROPE: RESIDUAL DNA TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 162
TABLE 141 ASIA PACIFIC: RESIDUAL DNA TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 162
TABLE 142 LATIN AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2023–2030 (USD MILLION) 163
TABLE 143 MIDDLE EAST: RESIDUAL DNA TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION,
2023–2030 (USD MILLION) 163
TABLE 144 GCC COUNTRIES: RESIDUAL DNA TESTING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2023–2030 (USD MILLION) 163
TABLE 145 RESIDUAL DNA TESTING PRODUCTS MARKET FOR CROS & CDMOS,
BY REGION, 2023–2030 (USD MILLION) 164
TABLE 146 NORTH AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 165
TABLE 147 EUROPE: RESIDUAL DNA TESTING PRODUCTS MARKET FOR CROS & CDMOS,
BY COUNTRY, 2023–2030 (USD MILLION) 165
TABLE 148 ASIA PACIFIC: RESIDUAL DNA TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 166
TABLE 149 LATIN AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 166
TABLE 150 MIDDLE EAST: RESIDUAL DNA TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY REGION, 2023–2030 (USD MILLION) 166
TABLE 151 GCC COUNTRIES: RESIDUAL DNA TESTING PRODUCTS MARKET FOR CROS & CDMOS, BY COUNTRY, 2023–2030 (USD MILLION) 167
TABLE 152 RESIDUAL DNA TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 167
TABLE 153 NORTH AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 168
TABLE 154 EUROPE: RESIDUAL DNA TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 168
TABLE 155 ASIA PACIFIC: RESIDUAL DNA TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 169
TABLE 156 LATIN AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 169
TABLE 157 MIDDLE EAST: RESIDUAL DNA TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 170
TABLE 158 GCC COUNTRIES: RESIDUAL DNA TESTING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 170
TABLE 159 RESIDUAL DNA TESTING SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 172
TABLE 160 RESIDUAL DNA TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 173
TABLE 161 NORTH AMERICA: RESIDUAL DNA TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2023–2030 (USD MILLION) 173
TABLE 162 EUROPE: RESIDUAL DNA TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 174
TABLE 163 ASIA PACIFIC: RESIDUAL DNA TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023–2030 (USD MILLION) 174
TABLE 164 LATIN AMERICA: RESIDUAL DNA TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2023–2030 (USD MILLION) 175
TABLE 165 MIDDLE EAST: RESIDUAL DNA TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION) 175
TABLE 166 GCC COUNTRIES: RESIDUAL DNA TESTING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY,
2023–2030 (USD MILLION) 175
TABLE 167 RESIDUAL DNA TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 176
TABLE 168 NORTH AMERICA: RESIDUAL DNA TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 177
TABLE 169 EUROPE: RESIDUAL DNA TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 177
TABLE 170 ASIA PACIFIC: RESIDUAL DNA TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 178
TABLE 171 LATIN AMERICA: RESIDUAL DNA TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 178
TABLE 172 MIDDLE EAST: RESIDUAL DNA TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023–2030 (USD MILLION) 178
TABLE 173 GCC COUNTRIES: RESIDUAL DNA TESTING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023–2030 (USD MILLION) 179
TABLE 174 RESIDUAL DNA TESTING MARKET, BY REGION, 2023–2030 (USD MILLION) 181
TABLE 175 RESIDUAL DNA TESTING PRODUCTS MARKET, BY REGION,
2023–2030 (USD MILLION) 181
TABLE 176 RESIDUAL DNA TESTING SERVICES MARKET, BY REGION,
2023–2030 (USD MILLION) 182
TABLE 177 NORTH AMERICA: RESIDUAL DNA TESTING MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 184
TABLE 178 NORTH AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 185
TABLE 179 NORTH AMERICA: RESIDUAL DNA TESTING SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 185
TABLE 180 NORTH AMERICA: RESIDUAL DNA TESTING MARKET,
BY OFFERING, 2023–2030 (USD MILLION) 185
TABLE 181 NORTH AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 186
TABLE 182 NORTH AMERICA: RESIDUAL DNA TESTING MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 186
TABLE 183 NORTH AMERICA: RESIDUAL DNA TESTING MARKET,
BY TEST TYPE, 2023–2030 (USD MILLION) 186
TABLE 184 NORTH AMERICA: RESIDUAL DNA TESTING MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 187
TABLE 185 NORTH AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 187
TABLE 186 NORTH AMERICA: RESIDUAL DNA TESTING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 187
TABLE 187 US: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 189
TABLE 188 US: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 189
TABLE 189 US: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 189
TABLE 190 US: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 190
TABLE 191 US: RESIDUAL DNA TESTING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 190
TABLE 192 US: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER,
2023–2030 (USD MILLION) 190
TABLE 193 US: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 191
TABLE 194 CANADA: RESIDUAL DNA TESTING MARKET, BY OFFERING,
2023–2030 (USD MILLION) 191
TABLE 195 CANADA: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 192
TABLE 196 CANADA: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 192
TABLE 197 CANADA: RESIDUAL DNA TESTING MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 192
TABLE 198 CANADA: RESIDUAL DNA TESTING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 193
TABLE 199 CANADA: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 193
TABLE 200 CANADA: RESIDUAL DNA TESTING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 193
TABLE 201 EUROPE: RESIDUAL DNA TESTING MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 195
TABLE 202 EUROPE: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 195
TABLE 203 EUROPE: RESIDUAL DNA TESTING SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 196
TABLE 204 EUROPE: RESIDUAL DNA TESTING MARKET, BY OFFERING,
2023–2030 (USD MILLION) 196
TABLE 205 EUROPE: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 196
TABLE 206 EUROPE: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 197
TABLE 207 EUROPE: RESIDUAL DNA TESTING MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 197
TABLE 208 EUROPE: RESIDUAL DNA TESTING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 197
TABLE 209 EUROPE: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 198
TABLE 210 EUROPE: RESIDUAL DNA TESTING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 198
TABLE 211 GERMANY: RESIDUAL DNA TESTING MARKET, BY OFFERING,
2023–2030 (USD MILLION) 199
TABLE 212 GERMANY: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 199
TABLE 213 GERMANY: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 199
TABLE 214 GERMANY: RESIDUAL DNA TESTING MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 200
TABLE 215 GERMANY: RESIDUAL DNA TESTING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 200
TABLE 216 GERMANY: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 200
TABLE 217 GERMANY: RESIDUAL DNA TESTING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 201
TABLE 218 UK: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 202
TABLE 219 UK: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 202
TABLE 220 UK: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 202
TABLE 221 UK: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 203
TABLE 222 UK: RESIDUAL DNA TESTING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 203
TABLE 223 UK: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 203
TABLE 224 UK: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 204
TABLE 225 FRANCE: RESIDUAL DNA TESTING MARKET, BY OFFERING,
2023–2030 (USD MILLION) 205
TABLE 226 FRANCE: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 205
TABLE 227 FRANCE: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 205
TABLE 228 FRANCE: RESIDUAL DNA TESTING MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 206
TABLE 229 FRANCE: RESIDUAL DNA TESTING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 206
TABLE 230 FRANCE: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 206
TABLE 231 FRANCE: RESIDUAL DNA TESTING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 207
TABLE 232 ITALY: RESIDUAL DNA TESTING MARKET, BY OFFERING,
2023–2030 (USD MILLION) 207
TABLE 233 ITALY: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 208
TABLE 234 ITALY: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 208
TABLE 235 ITALY: RESIDUAL DNA TESTING MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 208
TABLE 236 ITALY: RESIDUAL DNA TESTING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 209
TABLE 237 ITALY: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER,
2023–2030 (USD MILLION) 209
TABLE 238 ITALY: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 209
TABLE 239 SPAIN: RESIDUAL DNA TESTING MARKET, BY OFFERING,
2023–2030 (USD MILLION) 210
TABLE 240 SPAIN: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 211
TABLE 241 SPAIN: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 211
TABLE 242 SPAIN: RESIDUAL DNA TESTING MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 211
TABLE 243 SPAIN: RESIDUAL DNA TESTING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 212
TABLE 244 SPAIN: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 212
TABLE 245 SPAIN: RESIDUAL DNA TESTING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 212
TABLE 246 REST OF EUROPE: RESIDUAL DNA TESTING MARKET,
BY OFFERING, 2023–2030 (USD MILLION) 213
TABLE 247 REST OF EUROPE: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 213
TABLE 248 REST OF EUROPE: RESIDUAL DNA TESTING MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 214
TABLE 249 REST OF EUROPE: RESIDUAL DNA TESTING MARKET,
BY TEST TYPE, 2023–2030 (USD MILLION) 214
TABLE 250 REST OF EUROPE: RESIDUAL DNA TESTING MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 214
TABLE 251 REST OF EUROPE: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY END USER,2023–2030 (USD MILLION) 215
TABLE 252 REST OF EUROPE: RESIDUAL DNA TESTING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 215
TABLE 253 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 218
TABLE 254 ASIA PACIFIC: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 218
TABLE 255 ASIA PACIFIC: RESIDUAL DNA TESTING SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 219
TABLE 256 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET, BY OFFERING,
2023–2030 (USD MILLION) 219
TABLE 257 ASIA PACIFIC: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 219
TABLE 258 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 220
TABLE 259 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 220
TABLE 260 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 220
TABLE 261 ASIA PACIFIC: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 221
TABLE 262 ASIA PACIFIC: RESIDUAL DNA TESTING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 221
TABLE 263 CHINA: RESIDUAL DNA TESTING MARKET, BY OFFERING,
2023–2030 (USD MILLION) 222
TABLE 264 CHINA: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 222
TABLE 265 CHINA: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 223
TABLE 266 CHINA: RESIDUAL DNA TESTING MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 223
TABLE 267 CHINA: RESIDUAL DNA TESTING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 223
TABLE 268 CHINA: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 224
TABLE 269 CHINA: RESIDUAL DNA TESTING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 224
TABLE 270 JAPAN: RESIDUAL DNA TESTING MARKET, BY OFFERING,
2023–2030 (USD MILLION) 225
TABLE 271 JAPAN: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 225
TABLE 272 JAPAN: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 226
TABLE 273 JAPAN: RESIDUAL DNA TESTING MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 226
TABLE 274 JAPAN: RESIDUAL DNA TESTING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 226
TABLE 275 JAPAN: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 227
TABLE 276 JAPAN: RESIDUAL DNA TESTING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 227
TABLE 277 INDIA: RESIDUAL DNA TESTING MARKET, BY OFFERING,
2023–2030 (USD MILLION) 228
TABLE 278 INDIA: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 228
TABLE 279 INDIA: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 229
TABLE 280 INDIA: RESIDUAL DNA TESTING MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 229
TABLE 281 INDIA: RESIDUAL DNA TESTING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 229
TABLE 282 INDIA: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 230
TABLE 283 INDIA: RESIDUAL DNA TESTING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 230
TABLE 284 SOUTH KOREA: RESIDUAL DNA TESTING MARKET,
BY OFFERING, 2023–2030 (USD MILLION) 231
TABLE 285 SOUTH KOREA: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 231
TABLE 286 SOUTH KOREA: RESIDUAL DNA TESTING MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 231
TABLE 287 SOUTH KOREA: RESIDUAL DNA TESTING MARKET,
BY TEST TYPE, 2023–2030 (USD MILLION) 232
TABLE 288 SOUTH KOREA: RESIDUAL DNA TESTING MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 232
TABLE 289 SOUTH KOREA: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 232
TABLE 290 SOUTH KOREA: RESIDUAL DNA TESTING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 233
TABLE 291 AUSTRALIA: RESIDUAL DNA TESTING MARKET, BY OFFERING,
2023–2030 (USD MILLION) 233
TABLE 292 AUSTRALIA: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 234
TABLE 293 AUSTRALIA: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 234
TABLE 294 AUSTRALIA: RESIDUAL DNA TESTING MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 234
TABLE 295 AUSTRALIA: RESIDUAL DNA TESTING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 235
TABLE 296 AUSTRALIA: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 235
TABLE 297 AUSTRALIA: RESIDUAL DNA TESTING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 235
TABLE 298 REST OF ASIA PACIFIC: RESIDUAL DNA TESTING MARKET,
BY OFFERING, 2023–2030 (USD MILLION) 236
TABLE 299 REST OF ASIA PACIFIC: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 236
TABLE 300 REST OF ASIA PACIFIC: RESIDUAL DNA TESTING MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 237
TABLE 301 REST OF ASIA PACIFIC: RESIDUAL DNA TESTING MARKET,
BY TEST TYPE, 2023–2030 (USD MILLION) 237
TABLE 302 REST OF ASIA PACIFIC: RESIDUAL DNA TESTING MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 237
TABLE 303 REST OF ASIA PACIFIC: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 238
TABLE 304 REST OF ASIA PACIFIC: RESIDUAL DNA TESTING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 238
TABLE 305 LATIN AMERICA: RESIDUAL DNA TESTING MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 239
TABLE 306 LATIN AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 239
TABLE 307 LATIN AMERICA: RESIDUAL DNA TESTING SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 240
TABLE 308 LATIN AMERICA: RESIDUAL DNA TESTING MARKET,
BY OFFERING, 2023–2030 (USD MILLION) 240
TABLE 309 LATIN AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 240
TABLE 310 LATIN AMERICA: RESIDUAL DNA TESTING MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 241
TABLE 311 LATIN AMERICA: RESIDUAL DNA TESTING MARKET,
BY TEST TYPE, 2023–2030 (USD MILLION) 241
TABLE 312 LATIN AMERICA: RESIDUAL DNA TESTING MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 241
TABLE 313 LATIN AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 242
TABLE 314 LATIN AMERICA: RESIDUAL DNA TESTING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 242
TABLE 315 BRAZIL: RESIDUAL DNA TESTING MARKET, BY OFFERING,
2023–2030 (USD MILLION) 243
TABLE 316 BRAZIL: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 243
TABLE 317 BRAZIL: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 243
TABLE 318 BRAZIL: RESIDUAL DNA TESTING MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 244
TABLE 319 BRAZIL: RESIDUAL DNA TESTING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 244
TABLE 320 BRAZIL: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER,
2023–2030 (USD MILLION) 244
TABLE 321 BRAZIL: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 245
TABLE 322 MEXICO: RESIDUAL DNA TESTING MARKET, BY OFFERING,
2023–2030 (USD MILLION) 245
TABLE 323 MEXICO: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 246
TABLE 324 MEXICO: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 246
TABLE 325 MEXICO: RESIDUAL DNA TESTING MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 246
TABLE 326 MEXICO: RESIDUAL DNA TESTING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 247
TABLE 327 MEXICO: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 247
TABLE 328 MEXICO: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 247
TABLE 329 REST OF LATIN AMERICA: RESIDUAL DNA TESTING MARKET,
BY OFFERING, 2023–2030 (USD MILLION) 248
TABLE 330 REST OF LATIN AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 248
TABLE 331 REST OF LATIN AMERICA: RESIDUAL DNA TESTING MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 249
TABLE 332 REST OF LATIN AMERICA: RESIDUAL DNA TESTING MARKET,
BY TEST TYPE, 2023–2030 (USD MILLION) 249
TABLE 333 REST OF LATIN AMERICA: RESIDUAL DNA TESTING MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 249
TABLE 334 REST OF LATIN AMERICA: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 250
TABLE 335 REST OF LATIN AMERICA: RESIDUAL DNA TESTING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 250
TABLE 336 MIDDLE EAST: RESIDUAL DNA TESTING MARKET, BY REGION,
2023–2030 (USD MILLION) 251
TABLE 337 MIDDLE EAST: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY REGION, 2023–2030 (USD MILLION) 251
TABLE 338 MIDDLE EAST: RESIDUAL DNA TESTING SERVICES MARKET,
BY REGION, 2023–2030 (USD MILLION) 252
TABLE 339 MIDDLE EAST: RESIDUAL DNA TESTING MARKET, BY OFFERING,
2023–2030 (USD MILLION) 252
TABLE 340 MIDDLE EAST: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 252
TABLE 341 MIDDLE EAST: RESIDUAL DNA TESTING MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 253
TABLE 342 MIDDLE EAST: RESIDUAL DNA TESTING MARKET,
BY TEST TYPE, 2023–2030 (USD MILLION) 253
TABLE 343 MIDDLE EAST: RESIDUAL DNA TESTING MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 253
TABLE 344 MIDDLE EAST: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 254
TABLE 345 MIDDLE EAST: RESIDUAL DNA TESTING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 254
TABLE 346 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 255
TABLE 347 GCC COUNTRIES: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 255
TABLE 348 GCC COUNTRIES: RESIDUAL DNA TESTING SERVICES MARKET,
BY COUNTRY, 2023–2030 (USD MILLION) 255
TABLE 349 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET,
BY OFFERING, 2023–2030 (USD MILLION) 256
TABLE 350 GCC COUNTRIES: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 256
TABLE 351 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 256
TABLE 352 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET,
BY TEST TYPE, 2023–2030 (USD MILLION) 257
TABLE 353 GCC COUNTRIES: RESIDUAL DNA TESTING MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 257
TABLE 354 GCC COUNTRIES: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 257
TABLE 355 GCC COUNTRIES: RESIDUAL DNA TESTING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 258
TABLE 356 KINGDOM OF SAUDI ARABIA: RESIDUAL DNA TESTING MARKET,
BY OFFERING, 2023–2030 (USD MILLION) 258
TABLE 357 KINGDOM OF SAUDI ARABIA: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 259
TABLE 358 KINGDOM OF SAUDI ARABIA: RESIDUAL DNA TESTING MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 259
TABLE 359 KINGDOM OF SAUDI ARABIA: RESIDUAL DNA TESTING MARKET,
BY TEST TYPE, 2023–2030 (USD MILLION) 259
TABLE 360 KINGDOM OF SAUDI ARABIA: RESIDUAL DNA TESTING MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 260
TABLE 361 KINGDOM OF SAUDI ARABIA: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 260
TABLE 362 KINGDOM OF SAUDI ARABIA: RESIDUAL DNA TESTING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 260
TABLE 363 UAE: RESIDUAL DNA TESTING MARKET, BY OFFERING, 2023–2030 (USD MILLION) 261
TABLE 364 UAE: RESIDUAL DNA TESTING PRODUCTS MARKET, BY TYPE,
2023–2030 (USD MILLION) 261
TABLE 365 UAE: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 262
TABLE 366 UAE: RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2023–2030 (USD MILLION) 262
TABLE 367 UAE: RESIDUAL DNA TESTING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 262
TABLE 368 UAE: RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER,
2023–2030 (USD MILLION) 263
TABLE 369 UAE: RESIDUAL DNA TESTING SERVICES MARKET, BY END USER,
2023–2030 (USD MILLION) 263
TABLE 370 REST OF GCC COUNTRIES: RESIDUAL DNA TESTING MARKET,
BY OFFERING, 2023–2030 (USD MILLION) 264
TABLE 371 REST OF GCC COUNTRIES: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 264
TABLE 372 REST OF GCC COUNTRIES: RESIDUAL DNA TESTING MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 264
TABLE 373 REST OF GCC COUNTRIES: RESIDUAL DNA TESTING MARKET,
BY TEST TYPE, 2023–2030 (USD MILLION) 265
TABLE 374 REST OF GCC COUNTRIES: RESIDUAL DNA TESTING MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 265
TABLE 375 REST OF GCC COUNTRIES: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 265
TABLE 376 REST OF GCC COUNTRIES: RESIDUAL DNA TESTING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 266
TABLE 377 REST OF MIDDLE EAST: RESIDUAL DNA TESTING MARKET,
BY OFFERING, 2023–2030 (USD MILLION) 266
TABLE 378 REST OF MIDDLE EAST: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 267
TABLE 379 REST OF MIDDLE EAST: RESIDUAL DNA TESTING MARKET,
BY TECHNOLOGY, 2023–2030 (USD MILLION) 267
TABLE 380 REST OF MIDDLE EAST: RESIDUAL DNA TESTING MARKET,
BY TEST TYPE, 2023–2030 (USD MILLION) 267
TABLE 381 REST OF MIDDLE EAST: RESIDUAL DNA TESTING MARKET,
BY APPLICATION, 2023–2030 (USD MILLION) 268
TABLE 382 REST OF MIDDLE EAST: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 268
TABLE 383 REST OF MIDDLE EAST: RESIDUAL DNA TESTING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 268
TABLE 384 AFRICA: RESIDUAL DNA TESTING MARKET, BY OFFERING,
2023–2030 (USD MILLION) 270
TABLE 385 AFRICA: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY TYPE, 2023–2030 (USD MILLION) 270
TABLE 386 AFRICA: RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY,
2023–2030 (USD MILLION) 270
TABLE 387 AFRICA: RESIDUAL DNA TESTING MARKET, BY TEST TYPE,
2023–2030 (USD MILLION) 271
TABLE 388 AFRICA: RESIDUAL DNA TESTING MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 271
TABLE 389 AFRICA: RESIDUAL DNA TESTING PRODUCTS MARKET,
BY END USER, 2023–2030 (USD MILLION) 271
TABLE 390 AFRICA: RESIDUAL DNA TESTING SERVICES MARKET,
BY END USER, 2023–2030 (USD MILLION) 272
TABLE 391 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN RESIDUAL
DNA TESTING MARKET 274
TABLE 392 RESIDUAL DNA TESTING MARKET: DEGREE OF COMPETITION 276
TABLE 393 RESIDUAL DNA TESTING MARKET: REGION FOOTPRINT 281
TABLE 394 RESIDUAL DNA TESTING MARKET: OFFERING FOOTPRINT 282
TABLE 395 RESIDUAL DNA TESTING MARKET: TECHNOLOGY FOOTPRINT 283
TABLE 396 RESIDUAL DNA TESTING MARKET: TEST TYPE FOOTPRINT 284
TABLE 397 RESIDUAL DNA TESTING MARKET: DETAILED LIST OF KEY STARTUPS/SMES 287
TABLE 398 RESIDUAL DNA TESTING MARKET: COMPETITIVE BENCHMARKING
OF KEY STARTUPS/SME PLAYERS 288
TABLE 399 RESIDUAL DNA TESTING MARKET: PRODUCT LAUNCHES,
JANUARY 2021–MAY 2025 291
TABLE 400 RESIDUAL DNA TESTING MARKET: DEALS, JANUARY 2021–MAY 2025 292
TABLE 401 RESIDUAL DNA TESTING MARKET: OTHER DEVELOPMENTS,
JANUARY 2021–MAY 2025 292
TABLE 402 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW 293
TABLE 403 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED 295
TABLE 404 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022–MAY 2025 296
TABLE 405 THERMO FISHER SCIENTIFIC INC.: OTHER DEVELOPMENTS,
JANUARY 2022–MAY 2025 296
TABLE 406 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW 298
TABLE 407 CHARLES RIVER LABORATORIES: PRODUCTS/SERVICES OFFERED 299
TABLE 408 CHARLES RIVER LABORATORIES: EXPANSIONS, JANUARY 2022–MAY 2025 300
TABLE 409 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 301
TABLE 410 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES OFFERED 302
TABLE 411 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025 303
TABLE 412 MERCK KGAA: COMPANY OVERVIEW 304
TABLE 413 MERCK KGAA: PRODUCTS/SERVICES OFFERED 305
TABLE 414 MERCK KGAA: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025 306
TABLE 415 MERCK KGAA: EXPANSIONS, JANUARY 2022–MAY 2025 306
TABLE 416 MARAVAI LIFESCIENCES: COMPANY OVERVIEW 308
TABLE 417 MARAVAI LIFESCIENCES: PRODUCTS/SERVICES OFFERED 310
TABLE 418 MARAVAI LIFESCIENCES: DEALS, JANUARY 2022–MAY 2025 311
TABLE 419 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 312
TABLE 420 EUROFINS SCIENTIFIC: PRODUCTS/SERVICES OFFERED 314
TABLE 421 EUROFINS SCIENTIFIC: DEALS, JANUARY 2022–MAY 2025 314
TABLE 422 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 315
TABLE 423 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED 317
TABLE 424 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2022–MAY 2025 318
TABLE 425 QIAGEN: COMPANY OVERVIEW 319
TABLE 426 QIAGEN: PRODUCTS/SERVICES OFFERED 321
TABLE 427 QIAGEN: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025 321
TABLE 428 FUJIFILM CORPORATION: COMPANY OVERVIEW 322
TABLE 429 FUJIFILM CORPORATION: PRODUCTS/SERVICES OFFERED 324
TABLE 430 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA.: COMPANY OVERVIEW 325
TABLE 431 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA.: PRODUCTS/SERVICES OFFERED 326
TABLE 432 HILLGENE BIOPHARMA CO., LTD.: COMPANY OVERVIEW 327
TABLE 433 HILLGENE BIOPHARMA CO., LTD.: PRODUCTS/SERVICES OFFERED 329
TABLE 434 REVVITY: COMPANY OVERVIEW 330
TABLE 435 REVVITY: PRODUCTS/SERVICES OFFERED 332
TABLE 436 REVVITY: PRODUCT LAUNCHES, JANUARY 2022–MAY 2025 332
TABLE 437 INTERTEK GROUP PLC: COMPANY OVERVIEW 333
TABLE 438 INTERTEK GROUP PLC: PRODUCTS/SERVICES OFFERED 334
TABLE 439 SARTORIUS AG: COMPANY OVERVIEW 335
TABLE 440 SARTORIUS AG: PRODUCTS/SERVICES OFFERED 336
TABLE 441 LONZA: COMPANY OVERVIEW 337
TABLE 442 LONZA: PRODUCTS/SERVICES OFFERED 338
TABLE 443 WUXI APPTEC: COMPANY OVERVIEW 339
TABLE 444 WUXI APPTEC: PRODUCTS/SERVICES OFFERED 340
TABLE 445 TRANSGEN BIOTECH CO., LTD.: COMPANY OVERVIEW 341
TABLE 446 EAGLEBIO: COMPANY OVERVIEW 342
TABLE 447 YEASEN: COMPANY OVERVIEW 343
TABLE 448 ACROBIOSYSTEMS: COMPANY OVERVIEW 344
TABLE 449 CREATIVE BIOGENE: COMPANY OVERVIEW 345
TABLE 450 MINERVA BIOLABS GMBH: COMPANY OVERVIEW 346
TABLE 451 CREATIVE PROTEOMICS: COMPANY OVERVIEW 347
TABLE 452 AVANCE BIOSCIENCES: COMPANY OVERVIEW 348
TABLE 453 GENERI BIOTECH: COMPANY OVERVIEW 349
LIST OF FIGURES
FIGURE 1 RESIDUAL DNA TESTING MARKET SEGMENTATION & REGIONAL SCOPE 37
FIGURE 2 RESIDUAL DNA TESTING MARKET: YEARS CONSIDERED 39
FIGURE 3 RESIDUAL DNA TESTING MARKET: RESEARCH DESIGN 40
FIGURE 4 RESIDUAL DNA TESTING MARKET: BREAKDOWN OF PRIMARIES
(SUPPLY- AND DEMAND-SIDE PARTICIPANTS) 42
FIGURE 5 RESIDUAL DNA TESTING MARKET SIZE ESTIMATION
(SUPPLY-SIDE ANALYSIS), 2024 43
FIGURE 6 RESIDUAL DNA TESTING MARKET: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (BOTTOM-UP APPROACH) (2024) 44
FIGURE 7 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.:
REVENUE SHARE ANALYSIS (2024) 44
FIGURE 8 RESIDUAL DNA TESTING MARKET: INSIGHTS FROM PRIMARIES 45
FIGURE 9 RESIDUAL DNA TESTING MARKET: TOP-DOWN APPROACH 46
FIGURE 10 RESIDUAL DNA TESTING MARKET: CAGR PROJECTIONS 48
FIGURE 11 RESIDUAL DNA TESTING MARKET: DATA TRIANGULATION 49
FIGURE 12 RESIDUAL DNA TESTING MARKET, BY OFFERING, 2025 VS. 2030 (USD MILLION) 52
FIGURE 13 RESIDUAL DNA TESTING MARKET, BY TEST TYPE, 2025 VS. 2030 (USD MILLION) 53
FIGURE 14 RESIDUAL DNA TESTING MARKET, BY TECHNOLOGY,
2025 VS. 2030 (USD MILLION) 53
FIGURE 15 RESIDUAL DNA TESTING MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 54
FIGURE 16 RESIDUAL DNA TESTING PRODUCTS MARKET, BY END USER,
2025 VS. 2030 (USD MILLION) 55
FIGURE 17 RESIDUAL DNA TESTING SERVICES MARKET, BY END USER,
2025 VS. 2030 (USD MILLION) 55
FIGURE 18 REGIONAL ANALYSIS OF RESIDUAL DNA TESTING MARKET 56
FIGURE 19 INCREASE IN NUMBER OF BIOLOGICS AND BIOSIMILAR APPROVALS
TO DRIVE MARKET 57
FIGURE 20 US AND FINAL PRODUCT RELEASE TESTING ACCOUNTED FOR LARGEST
NORTH AMERICAN MARKET SHARE IN 2024 58
FIGURE 21 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES COMMANDED LARGEST MARKET SHARE IN 2024 58
FIGURE 22 CHINA TO WITNESS HIGHEST CAGR DURING STUDY PERIOD 59
FIGURE 23 RESIDUAL DNA TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 60
FIGURE 24 GLOBAL TOTAL PHARMACEUTICAL R&D SPEND, 2016–2030 64
FIGURE 25 RESIDUAL DNA TESTING MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 69
FIGURE 26 AVERAGE SELLING PRICE OF DNA QUANTIFICATION KITS,
BY KEY PLAYER, 2024 (USD) 70
FIGURE 27 AVERAGE SELLING PRICE TREND OF PCR SYSTEMS, BY KEY PLAYER,
2022–2024 (USD) 71
FIGURE 28 AVERAGE SELLING PRICE OF RESIDUAL DNA TESTING PRODUCTS,
BY REGION, 2024 (USD) 72
FIGURE 29 RESIDUAL DNA TESTING MARKET: VALUE CHAIN ANALYSIS 73
FIGURE 30 RESIDUAL DNA TESTING MARKET: ECOSYSTEM ANALYSIS 76
FIGURE 31 FUNDING AND NUMBER OF DEALS IN RESIDUAL DNA TESTING
MARKET, 2021–2024 78
FIGURE 32 TOP APPLICANTS OF RESIDUAL DNA TESTING PATENTS, 2014–2024 81
FIGURE 33 RESIDUAL DNA TESTING MARKET: PORTER’S FIVE FORCES ANALYSIS 88
FIGURE 34 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS, BY OFFERING 90
FIGURE 35 KEY BUYING CRITERIA, BY END USER 91
FIGURE 36 RESIDUAL DNA TESTING MARKET: KEY AI USE CASES 93
FIGURE 37 NORTH AMERICA: RESIDUAL DNA TESTING MARKET SNAPSHOT 184
FIGURE 38 ASIA PACIFIC: RESIDUAL DNA TESTING MARKET SNAPSHOT 217
FIGURE 39 REVENUE ANALYSIS OF KEY PLAYERS IN RESIDUAL DNA TESTING MARKET,
2020–2024 (USD MILLION) 275
FIGURE 40 MARKET SHARE ANALYSIS OF KEY PLAYERS IN RESIDUAL DNA TESTING
MARKET (2024) 276
FIGURE 41 RESIDUAL DNA TESTING MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2024 279
FIGURE 42 RESIDUAL DNA TESTING MARKET: COMPANY FOOTPRINT 280
FIGURE 43 RESIDUAL DNA TESTING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 286
FIGURE 44 WEV/EBITDA OF KEY VENDORS 289
FIGURE 45 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA
OF KEY VENDORS 289
FIGURE 46 RESIDUAL DNA TESTING MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 290
FIGURE 47 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT 294
FIGURE 48 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT 299
FIGURE 49 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT 302
FIGURE 50 MERCK KGAA: COMPANY SNAPSHOT 305
FIGURE 51 MARAVAI LIFESCIENCES: COMPANY SNAPSHOT 309
FIGURE 52 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT 313
FIGURE 53 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT 316
FIGURE 54 QIAGEN: COMPANY SNAPSHOT 320
FIGURE 55 FUJIFILM CORPORATION: COMPANY SNAPSHOT 323
FIGURE 56 SGS SOCIÉTÉ GÉNÉRALE DE SURVEILLANCE SA.: COMPANY SNAPSHOT 326
FIGURE 57 HILLGENE BIOPHARMA CO., LTD.: COMPANY SNAPSHOT 328
FIGURE 58 REVVITY: COMPANY SNAPSHOT 331
FIGURE 59 INTERTEK GROUP PLC: COMPANY SNAPSHOT 334
FIGURE 60 SARTORIUS AG: COMPANY SNAPSHOT 336
FIGURE 61 LONZA: COMPANY SNAPSHOT 338
FIGURE 62 WUXI APPTEC: COMPANY SNAPSHOT 340
MarketsandMarkets（マーケッツアンドマーケッツ）は広範な市場を対象にした市場調査レポートを出版しています。世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | USD9,150 | USD9,650 | USD11,500 |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 水性バリアコーティング市場 – 2030年までの世界予測 2025-07-03
- 工作機械市場 – 2032年までの世界予測 2025-07-03
- 軟組織修復市場 – 2030年までの世界予測 2025-07-02
- エポキシ樹脂市場 – 2030年までの世界予測 2025-07-02
- スマートガスメーター市場 – 2030年までの世界予測 2025-07-02